Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines Immunology
Research on cancer vaccines immunology discussed by scientists at Memorial Sloan-Kettering Cancer Center
March 18th, 2008
Investigators publish new data in the report 'Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector.' According to recent research from the United States, "Salmonella typhimurium engineered to deliver cancer/testis antigen NY-ESO-1 through type III secretion (S typhimurium-NY-ESO-1) was shown to be an efficient cancer vaccine construct in mice and to stimulate NY-ESO-1-specific CD8(+)/CD4(+) T cells in vitro in patients with cancer with NY-ESO-1 spontaneous immunity. We also showed that individuals without spontaneous immunity to NY-ESO-1 had specific CD4(+) T-cell precursors with high avidity to NY-ESO-1 under tight control by CD4(+)CD25(+) regulatory T...
Source: Cancer Weekly (2008-03-18)
|
|
Advertisement |
|
|
|
